_id
6911bd5eccc777a4e85d6263
Ticker
GLUE
Name
Monte Rosa Therapeutics Inc
Exchange
NASDAQ
Address
321 Harrison Avenue, Boston, MA, United States, 02118
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.monterosatx.com
Description
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Last Close
16.56
Volume
417032
Current Price
16.53
Change
-0.1811594202898405
Last Updated
2025-11-30T19:25:54.882Z
Image
data:image/webp;base64,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
Ipo Date
2021-06-24T00:00:00.000Z
Market Cap
1052954176
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.1005
Sentiment Sources
4
Rating
4.5556
Target Price
17.2
Strong Buy
6
Buy
2
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
12768000
Cost Of Revenue
2095000
Gross Profit
10673000
Operating Expenses
43648000
Operating Income
-32975000
Interest Expense
-
Pretax Income
-30258000
Net Income
-27081000
Eps
-0.32866187503923805
Dividends Per Share
-
Shares Outstanding
65117761
Income Tax Expense
-3177000
EBITDA
-28163000
Operating Margin
-258.26284461152886
Total Other Income Expense Net
2717000
Cash
208343000
Short Term Investments
182915000
Receivables
4965000
Inventories
-
Total Current Assets
401817000
Property Plant Equipment
52663000
Total Assets
459841000
Payables
14509000
Short Term Debt
4241000
Long Term Debt
-
Total Liabilities
214004000
Equity
245837000
Depreciation
2732000
Change In Working Capital
2420000
Cash From Operations
100428000
Capital Expenditures
651000
Cash From Investing
38138000
Cash From Financing
348000
Net Change In Cash
138914000
PE
50.5313
PB
5.5403981381565846
ROE
-11.015835696009958
ROA
-5.88920953112054
FCF
99777000
Fcf Percent
7.814614661654136
Piotroski FScore
2
Health Score
45
Deep Value Investing Score
5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
6.8
Garp Investing Score
3.5
Growth Investing Score
2.5
Momentum Investing Score
7
Net Net Investing Score
4
Quality Investing Score
4
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
12768000
Quarters > 0 > income Statement > cost Of Revenue
2095000
Quarters > 0 > income Statement > gross Profit
10673000
Quarters > 0 > income Statement > operating Expenses
43648000
Quarters > 0 > income Statement > operating Income
-32975000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-30258000
Quarters > 0 > income Statement > net Income
-27081000
Quarters > 0 > income Statement > eps
-0.32866187503923805
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
82397753
Quarters > 0 > income Statement > income Tax Expense
-3177000
Quarters > 0 > income Statement > EBITDA
-28163000
Quarters > 0 > income Statement > operating Margin
-258.26284461152886
Quarters > 0 > income Statement > total Other Income Expense Net
2717000
Quarters > 0 > balance Sheet > cash
208343000
Quarters > 0 > balance Sheet > short Term Investments
182915000
Quarters > 0 > balance Sheet > receivables
4965000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
401817000
Quarters > 0 > balance Sheet > property Plant Equipment
52663000
Quarters > 0 > balance Sheet > total Assets
459841000
Quarters > 0 > balance Sheet > payables
14509000
Quarters > 0 > balance Sheet > short Term Debt
4241000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
214004000
Quarters > 0 > balance Sheet > equity
245837000
Quarters > 0 > cash Flow > net Income
-27081000
Quarters > 0 > cash Flow > depreciation
2732000
Quarters > 0 > cash Flow > change In Working Capital
2420000
Quarters > 0 > cash Flow > cash From Operations
100428000
Quarters > 0 > cash Flow > capital Expenditures
651000
Quarters > 0 > cash Flow > cash From Investing
38138000
Quarters > 0 > cash Flow > cash From Financing
348000
Quarters > 0 > cash Flow > net Change In Cash
138914000
Quarters > 0 > ratios > PE
-0.32866187503923805
Quarters > 0 > ratios > PB
5.5403981381565846
Quarters > 0 > ratios > ROE
-11.015835696009958
Quarters > 0 > ratios > ROA
-5.88920953112054
Quarters > 0 > ratios > FCF
99777000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
7.814614661654136
Quarters > 0 > health Score
45
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
23194000
Quarters > 1 > income Statement > cost Of Revenue
2125000
Quarters > 1 > income Statement > gross Profit
23194000
Quarters > 1 > income Statement > operating Expenses
38748000
Quarters > 1 > income Statement > operating Income
-15554000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-11096000
Quarters > 1 > income Statement > net Income
-12295000
Quarters > 1 > income Statement > eps
-0.14959829056667615
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
82186768
Quarters > 1 > income Statement > income Tax Expense
1199000
Quarters > 1 > income Statement > EBITDA
-13429000
Quarters > 1 > income Statement > operating Margin
-67.06044666724152
Quarters > 1 > income Statement > total Other Income Expense Net
4458000
Quarters > 1 > balance Sheet > cash
69429000
Quarters > 1 > balance Sheet > short Term Investments
221165000
Quarters > 1 > balance Sheet > receivables
2370000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
299465000
Quarters > 1 > balance Sheet > property Plant Equipment
54726000
Quarters > 1 > balance Sheet > total Assets
359586000
Quarters > 1 > balance Sheet > payables
5581000
Quarters > 1 > balance Sheet > short Term Debt
4094000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
91506000
Quarters > 1 > balance Sheet > equity
268080000
Quarters > 1 > cash Flow > net Income
-12295000
Quarters > 1 > cash Flow > depreciation
2125000
Quarters > 1 > cash Flow > change In Working Capital
-28707000
Quarters > 1 > cash Flow > cash From Operations
-34720000
Quarters > 1 > cash Flow > capital Expenditures
1695000
Quarters > 1 > cash Flow > cash From Investing
25324000
Quarters > 1 > cash Flow > cash From Financing
365000
Quarters > 1 > cash Flow > net Change In Cash
-9031000
Quarters > 1 > ratios > PE
-0.14959829056667615
Quarters > 1 > ratios > PB
5.067693505819158
Quarters > 1 > ratios > ROE
-4.586317517159057
Quarters > 1 > ratios > ROA
-3.4192098691272745
Quarters > 1 > ratios > FCF
-36415000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-1.5700181081314133
Quarters > 1 > health Score
29
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
84929000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
84929000
Quarters > 2 > income Statement > operating Expenses
40893000
Quarters > 2 > income Statement > operating Income
44036000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
47707000
Quarters > 2 > income Statement > net Income
46885000
Quarters > 2 > income Statement > eps
0.5651762492218354
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
82956423
Quarters > 2 > income Statement > income Tax Expense
822000
Quarters > 2 > income Statement > EBITDA
46084000
Quarters > 2 > income Statement > operating Margin
51.85036913186308
Quarters > 2 > income Statement > total Other Income Expense Net
3671000
Quarters > 2 > balance Sheet > cash
78530000
Quarters > 2 > balance Sheet > short Term Investments
247544000
Quarters > 2 > balance Sheet > receivables
1408000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
332280000
Quarters > 2 > balance Sheet > property Plant Equipment
55599000
Quarters > 2 > balance Sheet > total Assets
393199000
Quarters > 2 > balance Sheet > payables
6489000
Quarters > 2 > balance Sheet > short Term Debt
3865000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
118039000
Quarters > 2 > balance Sheet > equity
275160000
Quarters > 2 > cash Flow > net Income
46885000
Quarters > 2 > cash Flow > depreciation
2048000
Quarters > 2 > cash Flow > change In Working Capital
-98635000
Quarters > 2 > cash Flow > cash From Operations
-45492000
Quarters > 2 > cash Flow > capital Expenditures
1587000
Quarters > 2 > cash Flow > cash From Investing
-100229000
Quarters > 2 > cash Flow > cash From Financing
14000
Quarters > 2 > cash Flow > net Change In Cash
-145724000
Quarters > 2 > ratios > PE
0.5651762492218354
Quarters > 2 > ratios > PB
4.983535659943306
Quarters > 2 > ratios > ROE
17.03917720598924
Quarters > 2 > ratios > ROA
11.923987599154627
Quarters > 2 > ratios > FCF
-47079000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.5543336198471664
Quarters > 2 > health Score
67
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
60647000
Quarters > 3 > income Statement > cost Of Revenue
2061000
Quarters > 3 > income Statement > gross Profit
60647000
Quarters > 3 > income Statement > operating Expenses
47643000
Quarters > 3 > income Statement > operating Income
13004000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
15601000
Quarters > 3 > income Statement > net Income
13437000
Quarters > 3 > income Statement > eps
0.2187127767521519
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
61436740
Quarters > 3 > income Statement > income Tax Expense
2164000
Quarters > 3 > income Statement > EBITDA
15065000
Quarters > 3 > income Statement > operating Margin
21.442115850742823
Quarters > 3 > income Statement > total Other Income Expense Net
2597000
Quarters > 3 > balance Sheet > cash
224254000
Quarters > 3 > balance Sheet > short Term Investments
147895000
Quarters > 3 > balance Sheet > receivables
173000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
377440000
Quarters > 3 > balance Sheet > property Plant Equipment
56314000
Quarters > 3 > balance Sheet > total Assets
438732000
Quarters > 3 > balance Sheet > payables
17215000
Quarters > 3 > balance Sheet > short Term Debt
3714000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
215796000
Quarters > 3 > balance Sheet > equity
222936000
Quarters > 3 > cash Flow > net Income
13437000
Quarters > 3 > cash Flow > depreciation
2061000
Quarters > 3 > cash Flow > change In Working Capital
109651000
Quarters > 3 > cash Flow > cash From Operations
128922000
Quarters > 3 > cash Flow > capital Expenditures
183000
Quarters > 3 > cash Flow > cash From Investing
-30896000
Quarters > 3 > cash Flow > cash From Financing
608000
Quarters > 3 > cash Flow > net Change In Cash
98634000
Quarters > 3 > ratios > PE
0.2187127767521519
Quarters > 3 > ratios > PB
4.555340152330714
Quarters > 3 > ratios > ROE
6.0272903434169445
Quarters > 3 > ratios > ROA
3.0626897513744153
Quarters > 3 > ratios > FCF
128739000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
2.1227595759064752
Quarters > 3 > health Score
68
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
75622000
Annuals > 0 > income Statement > cost Of Revenue
8121000
Annuals > 0 > income Statement > gross Profit
67501000
Annuals > 0 > income Statement > operating Expenses
148613000
Annuals > 0 > income Statement > operating Income
-81112000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-70130000
Annuals > 0 > income Statement > net Income
-72700000
Annuals > 0 > income Statement > eps
-0.9836283916339036
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
73910026
Annuals > 0 > income Statement > income Tax Expense
2570000
Annuals > 0 > income Statement > EBITDA
-72991000
Annuals > 0 > income Statement > operating Margin
-107.2597921239851
Annuals > 0 > income Statement > total Other Income Expense Net
10982000
Annuals > 0 > balance Sheet > cash
224254000
Annuals > 0 > balance Sheet > short Term Investments
147895000
Annuals > 0 > balance Sheet > receivables
173000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
377440000
Annuals > 0 > balance Sheet > property Plant Equipment
56314000
Annuals > 0 > balance Sheet > total Assets
438732000
Annuals > 0 > balance Sheet > payables
17215000
Annuals > 0 > balance Sheet > short Term Debt
3714000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
215796000
Annuals > 0 > balance Sheet > equity
222936000
Annuals > 0 > cash Flow > net Income
-72700000
Annuals > 0 > cash Flow > depreciation
8121000
Annuals > 0 > cash Flow > change In Working Capital
91397000
Annuals > 0 > cash Flow > cash From Operations
41996000
Annuals > 0 > cash Flow > capital Expenditures
3988000
Annuals > 0 > cash Flow > cash From Investing
-44452000
Annuals > 0 > cash Flow > cash From Financing
98892000
Annuals > 0 > cash Flow > net Change In Cash
96436000
Annuals > 0 > ratios > PE
-0.9836283916339036
Annuals > 0 > ratios > PB
5.360844010926903
Annuals > 0 > ratios > ROE
-32.610255858183514
Annuals > 0 > ratios > ROA
-16.570480384380442
Annuals > 0 > ratios > FCF
38008000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
0.5026050620189891
Annuals > 0 > health Score
45
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
6222000
Annuals > 1 > income Statement > gross Profit
-6222000
Annuals > 1 > income Statement > operating Expenses
137089000
Annuals > 1 > income Statement > operating Income
-143311000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-135014000
Annuals > 1 > income Statement > net Income
-135352000
Annuals > 1 > income Statement > eps
-2.6334630952207467
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
51396961
Annuals > 1 > income Statement > income Tax Expense
338000
Annuals > 1 > income Statement > EBITDA
-137089000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
8297000
Annuals > 1 > balance Sheet > cash
128101000
Annuals > 1 > balance Sheet > short Term Investments
104312000
Annuals > 1 > balance Sheet > receivables
505000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
236212000
Annuals > 1 > balance Sheet > property Plant Equipment
62611000
Annuals > 1 > balance Sheet > total Assets
303755000
Annuals > 1 > balance Sheet > payables
11152000
Annuals > 1 > balance Sheet > short Term Debt
3162000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
124505000
Annuals > 1 > balance Sheet > equity
179250000
Annuals > 1 > cash Flow > net Income
-135352000
Annuals > 1 > cash Flow > depreciation
6222000
Annuals > 1 > cash Flow > change In Working Capital
72466000
Annuals > 1 > cash Flow > cash From Operations
-43802000
Annuals > 1 > cash Flow > capital Expenditures
19041000
Annuals > 1 > cash Flow > cash From Investing
88801000
Annuals > 1 > cash Flow > cash From Financing
27492000
Annuals > 1 > cash Flow > net Change In Cash
72491000
Annuals > 1 > ratios > PE
-2.6334630952207467
Annuals > 1 > ratios > PB
4.636478992301256
Annuals > 1 > ratios > ROE
-75.51018131101813
Annuals > 1 > ratios > ROA
-44.55959572681931
Annuals > 1 > ratios > FCF
-62843000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
26
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
8559000
Annuals > 2 > income Statement > gross Profit
-8559000
Annuals > 2 > income Statement > operating Expenses
112384000
Annuals > 2 > income Statement > operating Income
-112384000
Annuals > 2 > income Statement > interest Expense
3764000
Annuals > 2 > income Statement > pretax Income
-108501000
Annuals > 2 > income Statement > net Income
-108501000
Annuals > 2 > income Statement > eps
-2.297417789726593
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
47227370
Annuals > 2 > income Statement > income Tax Expense
-3883000
Annuals > 2 > income Statement > EBITDA
-108639000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
3883000
Annuals > 2 > balance Sheet > cash
54912000
Annuals > 2 > balance Sheet > short Term Investments
207914000
Annuals > 2 > balance Sheet > receivables
7656000
Annuals > 2 > balance Sheet > inventories
960000
Annuals > 2 > balance Sheet > total Current Assets
275886000
Annuals > 2 > balance Sheet > property Plant Equipment
61907000
Annuals > 2 > balance Sheet > total Assets
342389000
Annuals > 2 > balance Sheet > payables
7862000
Annuals > 2 > balance Sheet > short Term Debt
3127000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
70976000
Annuals > 2 > balance Sheet > equity
271413000
Annuals > 2 > cash Flow > net Income
-108501000
Annuals > 2 > cash Flow > depreciation
3745000
Annuals > 2 > cash Flow > change In Working Capital
-2134000
Annuals > 2 > cash Flow > cash From Operations
-92466000
Annuals > 2 > cash Flow > capital Expenditures
12911000
Annuals > 2 > cash Flow > cash From Investing
-219219000
Annuals > 2 > cash Flow > cash From Financing
20466000
Annuals > 2 > cash Flow > net Change In Cash
-291219000
Annuals > 2 > ratios > PE
-2.297417789726593
Annuals > 2 > ratios > PB
2.8136698422698987
Annuals > 2 > ratios > ROE
-39.97634601142907
Annuals > 2 > ratios > ROA
-31.689394227034164
Annuals > 2 > ratios > FCF
-105377000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
35
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
2132000
Annuals > 3 > income Statement > gross Profit
-2132000
Annuals > 3 > income Statement > operating Expenses
72882000
Annuals > 3 > income Statement > operating Income
-72882000
Annuals > 3 > income Statement > interest Expense
1076000
Annuals > 3 > income Statement > pretax Income
-73958000
Annuals > 3 > income Statement > net Income
-73958000
Annuals > 3 > income Statement > eps
-1.5892653866903719
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
46535966
Annuals > 3 > income Statement > income Tax Expense
-2016000
Annuals > 3 > income Statement > EBITDA
-70750000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-1076000
Annuals > 3 > balance Sheet > cash
346071000
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
348666000
Annuals > 3 > balance Sheet > property Plant Equipment
12325000
Annuals > 3 > balance Sheet > total Assets
366329000
Annuals > 3 > balance Sheet > payables
6558000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
18814000
Annuals > 3 > balance Sheet > equity
347515000
Annuals > 3 > cash Flow > net Income
-73958000
Annuals > 3 > cash Flow > depreciation
2132000
Annuals > 3 > cash Flow > change In Working Capital
6286000
Annuals > 3 > cash Flow > cash From Operations
-59363000
Annuals > 3 > cash Flow > capital Expenditures
9732000
Annuals > 3 > cash Flow > cash From Investing
-9653000
Annuals > 3 > cash Flow > cash From Financing
377562000
Annuals > 3 > cash Flow > net Change In Cash
308546000
Annuals > 3 > ratios > PE
-1.5892653866903719
Annuals > 3 > ratios > PB
2.165335511330446
Annuals > 3 > ratios > ROE
-21.28195905212725
Annuals > 3 > ratios > ROA
-20.188955829322822
Annuals > 3 > ratios > FCF
-69095000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
34
Valuation > metrics > PE
50.5313
Valuation > metrics > PB
5.5403981381565846
Valuation > final Score
1
Valuation > verdict
93.4% Overvalued
Profitability > metrics > ROE
-11.015835696009958
Profitability > metrics > ROA
-6.739635207071876
Profitability > metrics > Net Margin
-2.1210056390977443
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8705117618584672
Risk > metrics > Interest Coverage
-15.739856801909308
Risk > final Score
-15
Risk > verdict
High
Liquidity > metrics > Current Ratio
21.43024
Liquidity > metrics > Quick Ratio
21.43024
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
29.32306494180842
Prev Valuations > 1
50.164643400566945
Prev Valuations > 2
54.446598476692856
Prev Profitabilities > 0
0
Prev Profitabilities > 1
94
Prev Profitabilities > 2
53
Prev Risks > 0
33
Prev Risks > 1
100
Prev Risks > 2
88
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:45:01.252Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-12
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.1598
Earnings History > 0 > eps Difference
0.1598
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-06
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.33
Earnings History > 1 > eps Estimate
-0.36
Earnings History > 1 > eps Difference
0.03
Earnings History > 1 > surprise Percent
8.3333
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-07
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.15
Earnings History > 2 > eps Estimate
-0.38
Earnings History > 2 > eps Difference
0.23
Earnings History > 2 > surprise Percent
60.5263
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-08
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0.57
Earnings History > 3 > eps Estimate
-0.44
Earnings History > 3 > eps Difference
1.01
Earnings History > 3 > surprise Percent
229.5455
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-20
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.3581
Earnings History > 4 > eps Estimate
0.18
Earnings History > 4 > eps Difference
-0.5381
Earnings History > 4 > surprise Percent
-298.9444
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-07
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.29
Earnings History > 5 > eps Estimate
-0.47
Earnings History > 5 > eps Difference
0.18
Earnings History > 5 > surprise Percent
38.2979
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-08
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.43
Earnings History > 6 > eps Estimate
-0.52
Earnings History > 6 > eps Difference
0.09
Earnings History > 6 > surprise Percent
17.3077
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-09
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.53
Earnings History > 7 > eps Estimate
-0.57
Earnings History > 7 > eps Difference
0.04
Earnings History > 7 > surprise Percent
7.0175
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-14
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.58
Earnings History > 8 > eps Estimate
-0.33
Earnings History > 8 > eps Difference
-0.25
Earnings History > 8 > surprise Percent
-75.7576
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-09
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.7
Earnings History > 9 > eps Estimate
-0.72
Earnings History > 9 > eps Difference
0.02
Earnings History > 9 > surprise Percent
2.7778
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-10
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.71
Earnings History > 10 > eps Estimate
-0.7
Earnings History > 10 > eps Difference
-0.01
Earnings History > 10 > surprise Percent
-1.4286
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-11
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
BeforeMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.65
Earnings History > 11 > eps Estimate
-0.68
Earnings History > 11 > eps Difference
0.03
Earnings History > 11 > surprise Percent
4.4118
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-16
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.63
Earnings History > 12 > eps Estimate
-0.62
Earnings History > 12 > eps Difference
-0.01
Earnings History > 12 > surprise Percent
-1.6129
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-10
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-0.58
Earnings History > 13 > eps Estimate
-0.6
Earnings History > 13 > eps Difference
0.02
Earnings History > 13 > surprise Percent
3.3333
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-11
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.57
Earnings History > 14 > eps Estimate
-0.54
Earnings History > 14 > eps Difference
-0.03
Earnings History > 14 > surprise Percent
-5.5556
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-11
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.51
Earnings History > 15 > eps Estimate
-0.52
Earnings History > 15 > eps Difference
0.01
Earnings History > 15 > surprise Percent
1.9231
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-29
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.93
Earnings History > 16 > eps Estimate
-0.5
Earnings History > 16 > eps Difference
-0.43
Earnings History > 16 > surprise Percent
-86
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-10
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.43
Earnings History > 17 > eps Estimate
-0.44
Earnings History > 17 > eps Difference
0.01
Earnings History > 17 > surprise Percent
2.2727
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-12
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
BeforeMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-3.63
Earnings History > 18 > eps Estimate
-0.4
Earnings History > 18 > eps Difference
-3.23
Earnings History > 18 > surprise Percent
-807.5
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-06-25
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
AfterMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-3.06
Earnings History > 19 > eps Estimate
-0.59
Earnings History > 19 > eps Difference
-2.47
Earnings History > 19 > surprise Percent
-418.6441
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-31
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-7.1822
Earnings History > 20 > eps Estimate
0
Earnings History > 20 > eps Difference
-7.1822
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2019-12-31
Earnings History > 21 > report Date
2020-03-31
Earnings History > 21 > date
2019-12-31
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-3.0376
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
-3.0376
Earnings History > 21 > surprise Percent
-
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry Sahm
Read more →'Stick and glue' method enables more precise biomolecule tracking in cells Phys.org
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$17.2
Analyst Picks
Strong Buy
6
Buy
2
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 119.94% of the total shares of Monte Rosa Therapeutics Inc
1.
NEA Management Company, LLC(12.4553%)
since
2025/06/30
2.
T. Rowe Price Associates, Inc.(10.2424%)
since
2025/06/30
3.
Bvf Inc(9.1648%)
since
2025/06/30
4.
Versant Venture Management LLC(9.1531%)
since
2025/06/30
5.
Baker Bros Advisors LP(7.9601%)
since
2025/06/30
6.
BlackRock Inc(6.2281%)
since
2025/06/30
7.
venBio Select Advisor LLC(6.0315%)
since
2025/06/30
8.
Suvretta Capital Management, LLC(5.4405%)
since
2025/06/30
9.
Vanguard Group Inc(5.0851%)
since
2025/06/30
10.
US Small-Cap Growth II Equity Comp(4.7198%)
since
2025/06/30
11.
T. Rowe Price New Horizons(4.594%)
since
2025/07/31
12.
FMR Inc(3.7048%)
since
2025/06/30
13.
Vanguard Total Stock Mkt Idx Inv(3.0439%)
since
2025/07/31
14.
Aisling Capital Management LP(2.384%)
since
2025/06/30
15.
Alphabet Inc(2.3705%)
since
2025/06/30
16.
HBM Healthcare Investments AG Ord(2.2783%)
since
2025/06/30
17.
AQR Capital Management LLC(2.0789%)
since
2025/06/30
18.
FIAM Small Cap Core CIT Cl B(2.0375%)
since
2025/06/30
19.
Geode Capital Management, LLC(1.8202%)
since
2025/06/30
20.
iShares Russell 2000 ETF(1.7814%)
since
2025/08/31
21.
T. Rowe Price Health Sciences(1.688%)
since
2025/07/31
22.
T. Rowe Price New Horizons Tr-A(1.4607%)
since
2025/06/30
23.
State Street Corp(1.3469%)
since
2025/06/30
24.
Northern Trust Corp(1.2329%)
since
2025/06/30
25.
Parkwood LLC(1.1464%)
since
2025/06/30
26.
Renaissance Technologies Corp(0.996%)
since
2025/06/30
27.
Morgan Stanley - Brokerage Accounts(0.9237%)
since
2025/06/30
28.
T. Rowe Price Integrated US Sm Gr Eq(0.8686%)
since
2025/07/31
29.
T. Rowe Price Integrated US SmCapGrEq(0.8686%)
since
2025/06/30
30.
Strategic Advisers Fidelity US TtlStk(0.8153%)
since
2025/07/31
31.
Vanguard Institutional Extnd Mkt Idx Tr(0.7912%)
since
2025/07/31
32.
Royal Bank of Canada(0.7607%)
since
2025/06/30
33.
Fidelity Small Cap Index(0.758%)
since
2025/06/30
34.
Fidelity Series Small Cap Core(0.6772%)
since
2025/06/30
35.
iShares Russell 2000 Value ETF(0.655%)
since
2025/08/31
36.
Avantis US Small Cap Value ETF(0.5281%)
since
2025/08/30
37.
NT Quality Small Cap Value(0.5101%)
since
2025/06/30
38.
Northern Small Cap Value(0.5101%)
since
2025/06/30
39.
iShares Biotechnology ETF(0.4398%)
since
2025/08/31
40.
Fidelity Extended Market Index(0.3871%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.1598
Date
2025-09-30
EPS Actual
-0.33
EPS Estimate
-0.36
EPS Difference
0.03
Surprise Percent
8.3333%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.